首页> 外文期刊>American journal of therapeutics >Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products
【24h】

Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products

机译:在设计蛋白质,抗体和血浆衍生产品的儿科研究中的药代动力学注意事项

获取原文
获取原文并翻译 | 示例
           

摘要

Ignoring the principles of pediatric pharmacology can have serious consequences. Therefore, it is necessary to understand and recognize the impact of developmental processes in children. It is now well recognized that age and the disease state can alter the pharmacokinetics (PKs) of a drug, as a result adjustment in dosing regimen in children as compared with the adults is essential. This review emphasizes on the importance of PK studies in pediatric population for macromolecules. Macromolecules differ from small molecules in many respects, and it is necessary to have a thorough understanding of the behavior of macromolecules in the body across different age groups. The review highlights that like small molecules, the PKs of macromolecules in pediatric population also differ from adults, hence, a PK study is essential in pediatrics for appropriate dose selection in this population. The review also takes a critical look on the many extrapolation techniques to predict PK parameters in pediatrics from adult data.
机译:忽视小儿药理学原理可能会产生严重后果。因此,有必要了解和认识发育过程对儿童的影响。现在已经众所周知,年龄和疾病状态会改变药物的药代动力学(PKs),因此与成年人相比,调整儿童的给药方案至关重要。这篇综述强调了小儿PK研究对大分子的重要性。大分子在许多方面都与小分子不同,因此有必要全面了解大分子在不同年龄段中的行为。该评论强调指出,与小分子一样,小儿人群中大分子的PKs也与成年人不同,因此,对于该人群中适当选择剂量,小儿科学中的PK研究至关重要。该评论还对从成人数据预测儿科患者PK参数的许多外推技术进行了批判性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号